{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel", "query": { "intervention": "Torisel" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 645, "total_pages": 65, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T21:13:06.318Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01154335", "title": "Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "OSI-906", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2010-07", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2022-05-03", "last_synced_at": "2026-09-11T21:13:06.318Z", "location_count": 2, "location_summary": "Fort Myers, Florida • Nashville, Tennessee", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01154335" }, { "nct_id": "NCT02693535", "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Multiple Myeloma", "Advanced Solid Tumors" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Trastuzumab and Pertuzumab", "type": "DRUG" }, { "name": "Vemurafenib and Cobimetinib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Nivolumab and Ipilimumab", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" }, { "name": "Atezolizumab and Talazoparib", "type": "DRUG" }, { "name": "Tucatinib plus Trastuzumab Subcutaneous (SC)", "type": "DRUG" }, { "name": "Futibatinib", "type": "DRUG" }, { "name": "Dabrafenib plus Trametinib", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki (TDxD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Society of Clinical Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 4200, "start_date": "2016-03-14", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-11T21:13:06.318Z", "location_count": 174, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02693535" }, { "nct_id": "NCT01204450", "title": "Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Neuroblastoma", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 7, "start_date": "2009-11", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2016-12-23", "last_synced_at": "2026-09-11T21:13:06.318Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Charlotte, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204450" }, { "nct_id": "NCT02678143", "title": "Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Hematopoietic stem cell transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 1, "start_date": "2016-04-26", "completion_date": "2021-11-16", "has_results": false, "last_update_posted_date": "2022-02-14", "last_synced_at": "2026-09-11T21:13:06.318Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02678143" }, { "nct_id": "NCT01309022", "title": "Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Mycophenolic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2016-02-09", "last_synced_at": "2026-09-11T21:13:06.318Z", "location_count": 3, "location_summary": "Miami, Florida • Boston, Massachusetts • St Louis, Missouri", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01309022" }, { "nct_id": "NCT01625351", "title": "A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewing Sarcoma", "Gastrointestinal Tumor", "Germ Cell Tumor", "Hepatic Tumor", "Lymphoma", "Wilms Tumor", "Rhabdoid Tumor", "Clear Cell Carcinoma", "Renal Cell Carcinoma", "Melanoma", "Neuroblastoma", "Rhabdomyosarcoma", "Non-rhabdomyosarcoma" ], "interventions": [ { "name": "alemtuzumab", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "stem cells", "type": "BIOLOGICAL" }, { "name": "CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 23, "start_date": "2012-08-20", "completion_date": "2020-02-10", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-11T21:13:06.318Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01625351" }, { "nct_id": "NCT01791088", "title": "Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sirolimus", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 56, "start_date": "2012-06-13", "completion_date": "2018-08-17", "has_results": false, "last_update_posted_date": "2019-04-22", "last_synced_at": "2026-09-11T21:13:06.318Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01791088" }, { "nct_id": "NCT01614795", "title": "Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Alveolar Soft Part Sarcoma", "Childhood Angiosarcoma", "Childhood Epithelioid Sarcoma", "Childhood Fibrosarcoma", "Childhood Gliosarcoma", "Childhood Leiomyosarcoma", "Childhood Liposarcoma", "Childhood Malignant Peripheral Nerve Sheath Tumor", "Childhood Synovial Sarcoma", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Osteosarcoma", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 46, "start_date": "2012-06-18", "completion_date": "2014-04-01", "has_results": true, "last_update_posted_date": "2018-12-11", "last_synced_at": "2026-09-11T21:13:06.318Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01614795" }, { "nct_id": "NCT00043979", "title": "Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "F-18 Fluorodeoxyglucose", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell donation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "5 Years to 35 Years" }, "enrollment_count": 60, "start_date": "2002-09-19", "completion_date": "2011-12-14", "has_results": true, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-09-11T21:13:06.318Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043979" }, { "nct_id": "NCT04562532", "title": "Firehawk Rapamycin Target Eluting Coronary Stent North American Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Microport Firehawk stent", "type": "DEVICE" }, { "name": "2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Shanghai MicroPort Medical (Group) Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1720, "start_date": "2021-02-17", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2024-07-24", "last_synced_at": "2026-09-11T21:13:06.318Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04562532" } ] }